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The impact of the presence and extent of valve calcification on long-term
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Purpose: The indication of percutaneous mitral commissurotomy (PMC) is
debated in patients (pts) with calcified mitral stenosis. We report outcome up
to 20 years according to the presence and the extent of valve calcification.
Methods: PMC was performed in 1024 consecutive pts between 1986 and
1995: 710 pts had non-calcified valves (NCAL group) and 314 had valve cal-
cification (CAL group) graded from 1 (mild) to 4 (extensive) using fluo-
roscopy. 177 pts (57%) were grade 1, 89 (28%) grade 2 and 48 (15%) grade
3 or 4.
Results: Good immediate results (GIR), defined as final valve area ≥1.5 cm²
without mitral regurgitation >2/4, were obtained in 93% in NCAL group vs.
80% in CAL group (p<0.0001). Among CAL group, GIR were 87% for grade
1 calcification vs. 72% for grades 2,3 and 4 (p=0.01).
Good functional results (GFR) were defined as survival without interven-
tion and in NYHA class I or II. 20-year rates of GFR were 38±3% for NCAL
group and 12±3% in CAL group (p<0.0001). Among pts with GIR, 20 year
rates of GFR were 40±3% in NCAL group vs. 21±3% in CAL group
(p<0.0001). In CAL group predictors of GFR after GIR were: younger age
(p=0.003), lower NYHA class (p=0.01), sinus rhythm (p=0.0002), lower post-
PMC mean gradient (p<0.0001) and a lower extent of valve calcification
(p=0.015).
According to the extent of valve calcification, 15-year rates of GFR after
GIR were 35±4% for pts in grade 1 vs. 19±4% for pts in grades 2, 3 and 4
(p=0.01).
Conclusion: This study further confirms the negative prognostic impact of
valve calcification on immediate and long-term results of PMC. PMC may,
however, be considered to defer valve surgery in selected patients. In partic-
ular, more than 1 patient out of 3 with mild calcification still benefits from
PMC 15 years after GIR. Young patients with few symptoms and in sinus
rhythm are likely to benefit from PMC, even with calcified valves.
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Left atrial remodeling after successful ballon mitral valvuloplasty
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Background: Left atrium (LA) remodeling has a crucial adverse impact on
outcome and prognosis in mitral stenosis. Few studies have reported the effect
of balloon mitral valvuloplasty (BMV) on LA volume and function. The aim
of this study was to assess the evolution of LA volume and compliance 1 and
6 months after successful BMV in patients in sinus rhythm.
Methods: 95 consecutive patients (70% women; age 31±8 years; range 19-
45) with severe mitral stenosis (mitral valve area ≤14 cm(2) ) who underwent
successful BMV were included prospectively. Using-dimensional echocardio-
graphy, and according to the prolate ellipse method, LA volume, area and
compliance (The maximum and the minimum LA volume were calculated
from apical four- and two-chamber zoomed views of the LA, using the biplane
method of discs. The difference between maximum and minimum LA volume
divided by the minimum LA volume was used as an index of atrial compli-
ance) were determined before BMV, and 1 month and 6 months after BMV.
LV global systolic function was evaluated by EF, by the biplane Simpson
method. Longitudinal left ventricular annular velocities were quantified by
spectral pulsed wave Doppler tissue velocity imaging
Results: Mitral valve area increased from 0.88±0.2 to 1.8±0.26 cm(2)
(P<0.0001). Mean mitral valve gradient (MVG) decreased from 14±6 to 6±
2 mmHg (P<0.0001) immediately after BMV. Indexed LA volume fell from
66±14 to 52±12 mL/m (2) (P=0.02) after BMV and to 45±13 mL/m (2) at
6 month (P<0.01) and an increase 0f the atrial index. Only patients with a
median LA volume ≥55 mL/m (2) before BMV had a significant reduction in
LA volume (P=0.0001). Decrease in LA volume was correlated with decreases
in PA-RV peak diastolic gradient (r=0.45, P=0.008) and MVG (r=0.35,
P=0.04). 
Conclusion: In patients with mitral stenosis in sinus rhythm, successful
BMV results in an immediate decrease in LA volume. This reduction, max-
imal immediately after BMV, correlates with decreases in MVG and PA-RV
peak diastolic gradient, and is significant only when LA volume before BMV
is severely enlarged.
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Impact of percutaneous mitral valve commissurotomy on right ventri-
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Fatima Wadrahmane, Nadia Zoubir, Saloua Laaraibi
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Introduction: The right ventricular function is an important determinant of
clinical symptoms, exercise capacity, pre-operative survival and post-opera-
tive outcome in patients with mitral stenosis (MS).
Objectif: The aim of this work was to evaluate the impact of percutaneous
mitral commissurotomy (PMC) on right ventricular function (RV) in patients
with severe mitral stenosis managed in Center of cardiology- University Hos-
pital IBN Rochd-Casablanca.
Methods and results: Of 150 patients there were 20 men and 130 women,
their mean age was 35±10 years. One hundred were in New York Heart Asso-
ciation class II, 40 in class III and 10 in class IV. Eighty patients with atrial
fibrillation.
Were studied before and after PMC. Multiple parameters of global and lon-
gitudinal RV function were assessed by conventional and tissue Doppler
imaging echocardiography
Mitral surface area and hemodynamic parameters improved significantly after
PMC; mean left atrial pressure fell from 18.76±6.18 to 10.65±4.38 mmHg
(P<0.001), mean transmitral gradient from 14.03±4.70 to 4.63±2.05mmHg
(p<0.001) and mitral valve area from 0.99±0.22 to 1.88±0.41 cm2 (p<0.001), in
the RV Tei index from 0.44+0.025 to 0.29+0.17 (P 1/4 0.021), in myocardial
acceleration during isovolumic contraction (IVA) at the lateral tricuspid annulus
from 0.36+0.11 m/s2 to 0.25+0.07 m/s2 (P 1/4 0.023), and in isovolumic
contraction velocities at the lateral tricuspid annulus from 11.03+3.37 cm/s to
8.50+2.04 cm/s (P 1/4 0.034).
Conclusion: This study demonstrates that, in patients with MS, global
right ventricular function improves in the majority of patients.
142
Increased Risk of Left Heart Valve Regurgitation Associated with
Benfluorex Use in Patients with Diabetes Mellitus. A Multicentre Study
Christophe Tribouilloy (1), Dan Rusinaru (2), Sylvestre Maréchaux (3),
Antoine Jeu (1), Stéphane Ederhy (4), Erwan Donal (5), Patricia Réant (6),
Elise Arnalsteen (7), Jacques Boulanger (8), Pierre-Vladimir Ennezat (9),
Thierry Garban (10), Yannick Jobic (11)
(1) CHU Amiens, Hôpital Sud, Service de cardiologie, Amiens, France –
(2) Amiens University Hospital, Cardiac Surgery, Amiens, France –
(3) Groupement Hospitalier de l’Institut Catholique de Lille, Lille, France
– (4) Hôpital Saint-Antoine, Université Pierre et Marie Curie, Paris VI,
cardiologie, Paris, France – (5) Centre Hospitalier Universitaire Rennes,
Hôpital Pontchaillou, Service de cardiologie et maladies vasculaires, Ren-
nes, France – (6) Hôpital Cardiologique Haut – Lévêque, CHU de Bor-
deaux, Pessac, France – (7) Centre Hospitalier de Beauvais, Service de
médecine interne et cardiologie, Beauvais, France – (8) Centre Hospita-
lier de Compiègne, Service de cardiologie, Compiègne, France – (9) Cen-
tre Hospitalier Régional et Universitaire de Lille, Lille, France –
(10) Hôpital Universitaire G et R Laennec, antes, antes, France –
(11) Hôpital de la Cavale Blanche, Brest, Département de cardiologie,
Brest, France
Background: Benfluorex was withdrawn from European markets in June
2010 following reports of an association with heart valve lesions. The link
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between benfluorex and valve regurgitations was based on small observational
studies and retrospective estimations. We therefore designed an echocardio-
graphy-based multicenter study to compare the frequency of left heart valve
regurgitations in diabetic patients exposed to benfluorex for at least three
months and in diabetic controls never exposed to the drug.
Methods: This reader-blinded controlled study conducted in ten centres in
France included prospectively between November 2009 and September 2011
393 consecutive diabetic subjects previously exposed to benfluorex referred
by primary care physicians for echocardiography screening and 393 diabetic
controls. Using propensity scores, 303 patients and 303 controls were matched
for age, gender, body mass index, smoking, dyslipidemia, hypertension, coro-
nary artery disease, and previous use of other drugs associated with valve
lesions. The main outcome measure was the frequency of mild or greater left
heart valve regurgitations.
Findings: In the matched sample, the frequency and relative risk (OR) of
mild or greater left heart valve regurgitations were significantly increased in
benfluorex patients compared to controls: 30·0% vs. 13·5% (OR 2.96[1·94-
4·53]) for aortic and/or mitral regurgitation; 21·1% vs. 5·0% (OR 5·63[3·08-
10·3]) for aortic regurgitation, and 17·2% vs. 10·2% (OR 1·99[1·22-3·25]) for
mitral regurgitation. The frequency of moderate left heart valve regurgitations
was also increased among benfluorex patients vs. controls (7·3% vs. 0·7%; OR
13·9[3·21-60·7]. 
Interpretation: Our results indicate that use of benfluorex is associated
with significant increase in the frequency of left heart valve regurgitations.
The natural history of benfluorex-induced valve abnormalities needs further
research.
143
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non invasive method to evaluate the prognosis of patients with myoto-
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Myotonic dystrophy (MD) is associated with a high risk of cardiac mor-
tality. Several causes are implicated, bradycardia, atrial and ventricular
arrhythmias, dilated cardiomyopathy and sudden death. Heart rate variability
evaluation (HRV) is a non invasive method used to evaluate the prognosis of
patients with heart disease. The purpose of the study was to evaluate the prog-
nostic value of HRV determination for the stratification risk and the follow-up
of patients with MD.
Methods: 156 patients, 79 men and 77 women, mean age 41±14 years, at
the inclusion, were recruited for a MD. Patients were asymptomatic at the
inclusion. The following studies were performed at the inclusion and repeated
4.5±3.5 years later in 124 of them. Recording of 24 hour Holter monitoring
and measurement of HRV in the time domain was calculated every 5 minutes
with the Elatec system; standard deviation of the mean RR intervals (SDNN)
(ms) was determined. Left ventricular ejection fraction (LVEF) was evaluated
at the same time by 2D echocardiography.
Results: LVEF decreased significantly from 62±8 to 58±11% (p< 0.03).
None of them had sustained ventricular tachycardia. 19 patients died (12%)
during the follow-up generally from cardiac and respiratory failure. Mean
values of SDNN did not change significantly between first inclusion
(126±42.5 ms) and last study (126±47 ms). At inclusion, SDNN was signifi-
cantly shorter in patients who died than in alive patients (109±50 msec vs
128±41) (p <0.025). Among the patients who died, initial SDNN was missing
in 6 patients, less than 100 msec in 10 patients and more than 100 msec in
only 3 patients. Among total population only 40 patients had an initial SDNN
<100 msec and 10 died (25%). Remaining patients had a SDNN >100 msec
and only 3 patients died (3%)(p< 0.0001).
Conclusions: The modifications of HRV during the follow-up were not
useful for the prediction of the occurrence of dilated cardiomyopathy or of
life-threatening arrhythmias in myotonic dystrophy, although LVEF decreased
with time. However, a low HRV (< 100msec) at the first evaluation was pre-
dictive of increasing mortality from 3 to 25%.
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Objectives: Fenfluramine derivatives have been associated with significant
risk of developing cardiac valvulopathy. This prospective study evaluated
characteristics of patients hospitalized in cardiology and who have been
exposed to these drugs.
Methods: Between july 2011 and february 2012, patients admitted in the
cardiology department, University Center of Montpellier, France, were ques-
tioned about past exposition to fenfluramine derivatives. In case of positive
response, a questionnaire assessing prescribing patterns and previous medical
history was proposed and echocardiography was performed. All usual
echocardiographic parameters were analysed. We applied criteria from the
French multicenter registry for diagnosis of drug-induced valvulopathy.
Results: Ninety patients exposed to the drugs were included. Sixty-seven
percent were women (n=60). Fifty-three percent had diabete (n=47). Ninety
percent were exposed to benfluorex (n=81). Mean treatment duration was
48 months (IC95%; 36,5-60,2). Valvular regurgitations were observed in
62,2% of patients (n=51) while 19% of patients (n=15) had pulmonary hyper-
tension. Distribution of valvulopathies is summarized in table 1. Highly pro-
bable induced valvulopathies were mild to moderate in all except 3 cases.
Conclusion: In absence of definite knowledge about evolution of drug-
induced valve disease, systematic questioning concerning fenfluramine deriv-
atives use could be recommended in hospitalized patients.
Table 1 – Distribution of regurgitations
Figure – Left heart regurgitations in patients vs. controls
Patients Mitral R Aortic R
HP 16 (20,3%) 8 (10,7%) 11 (14,3%)
PI 28 (34,1%) 20 (24,4%) 13(16,0%)
UI 22 (26,8%) 15 (18,3%) 11 (13,4%)
(HP: highly probable induced regurgitations; PI: possibly induced 
regurgitations; UI: unlikely induced regurgitations; R: regurgitation)
